Overview

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
PRIMARY: - To determine the toxicity and tolerability of intra-arterial hepatic oxaliplatin every three weeks administered in combination with systemic intravenous Fluorouracil, Leucovorin and bevacizumab to patients with advanced solid tumors metastatic to the liver. SECONDARY: - To document in a descriptive fashion the antitumor efficacy of this combination regimen. - To evaluate the feasibility and accuracy of an alternate radiographic assessment tool and compare with available tumor markers and RECIST guidelines. - To estimate in a descriptive fashion the development of extrahepatic tumor recurrences.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Bevacizumab
Fluorouracil
Leucovorin
Oxaliplatin